Filtered By:
Specialty: Neurology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 720 results found since Jan 2013.
Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis
ConclusionIn patients with symptomatic large artery extracranial or intracranial atherosclerosis, DAPT was superior to MAPT in preventing IS recurrence without increasing bleeding risks. The optimal DAPT regimens and duration of treatment in this population need to be clarified in further studies.
Source: Frontiers in Neurology - September 12, 2022 Category: Neurology Source Type: research
Real-time data on the prognosis of acute ischemic stroke patients in the Tochigi Clinical ObservatioNal registry for 1-year mortality of aCute ischEmic stRoke patieNt (T-CONCERN) study
ConclusionsOur study reveals the real-time survival data 1 year after the onset of a stroke, in-hospital and post-discharge mortality rates, and several issues associated with the treatment of acute ischemic strokes.
Source: Neurological Sciences - September 7, 2022 Category: Neurology Source Type: research
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention
Early stroke occurrence after ischemic stroke or transient ischemic attack (TIA) remains a significant risk despite advances in secondary prevention. Ischemic stroke is largely a thromboembolic disease, and major efforts to reduce the early risk of recurrent stroke in patients with non-cardioembolic stroke have focused on antiplatelet strategies.1 Improvements in outcome have been associated with novel antiplatelet strategies, but significant residual risk of ischemic stroke and the potential for major bleeding, including intracranial hemorrhage, limit the effectiveness of these options.
Source: Journal of Stroke and Cerebrovascular Diseases - August 27, 2022 Category: Neurology Authors: Mukul Sharma, Carlos A. Molina, Kazunori Toyoda, Daniel Bereczki, Scott E. Kasner, Helmi L. Lutsep, Georgios Tsivgoulis, George Ntaios, Anna Czlonkowska, Ashfaq Shuaib, Pierre Amarenco, Matthias Endres, Hans Christoph Diener, David Gailani, Anja Kahl, Mar Source Type: research
The effect of acupuncture on enteral nutrition and gastrointestinal dynamics in patients who have suffered a severe stroke
CONCLUSION: Acupuncture improved the enteral nutrition status of patients who had suffered a severe stroke and promoted gastrointestinal motility. The combination of acupuncture and early enteral nutrition could reduce damage to the gastrointestinal mucosal barrier caused by stress, changes in metabolism, and improved gastrointestinal function.PMID:35996236 | DOI:10.2174/1567202619666220822123023
Source: Current Neurovascular Research - August 23, 2022 Category: Neurology Authors: Liang Qin Xin-Xin Zhang Xin Jin Cai-Hong Cui Chun-Zhi Tang Source Type: research
Treatments in Ischemic Stroke: Current and Future
Background and Aim: Despite progress made over the last 30 years, stroke is still a leading cause of disability and mortality; likewise, its burden is expected to increase over the next decades, due to population growth and aging. The development of drugs with better safety-efficacy profiles as well as strategies able to improve ischemic stroke management from the pre-hospital setting is needed.Summary: The pathophysiology of ischemic stroke involves multiple pathways resulting in cerebral artery obstruction and brain tissue ischemia. To date, the only approved drug for acute ischemic stroke is intravenous thrombolytic alt...
Source: European Neurology - August 2, 2022 Category: Neurology Source Type: research
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention
Antiplatelet monotherapy is preferred over dual antiplatelet therapy (DAPT) for long-term secondary stroke prevention, owing at least in part to accumulated bleeding risks that outweigh potential benefits. However, right after a minor ischemic stroke or transient ischemic attack (TIA), the short-term risk of recurrent stroke is high, particularly in the first hours and days after the index event. This early period of heightened risk presents an important target for intervention and an opportunity to intensify antithrombotic treatment with DAPT in a more targeted way.
Source: JAMA Neurology - August 1, 2022 Category: Neurology Source Type: research
Start, Stop, Continue? The Benefit of Overlapping Intravenous Thrombolysis and Mechanical Thrombectomy
ConclusionThe presented results support the approach of continuing and completing a simultaneous administration of intravenous thrombolysis during mechanical thrombectomy procedures.
Source: Clinical Neuroradiology - July 26, 2022 Category: Neurology Source Type: research
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment
To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2022 Category: Neurology Authors: Kyohei Fujita, Shoko Fujii, Sakyo Hirai, Hiroto Yamaoka, Mariko Ishikawa, Jun Karakama, Kazunori Miki, Masataka Yoshimura, Shigeru Nemoto, Kazutaka Sumita Source Type: research
Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
Polycythemia vera (PV) is one of the myeloproliferative neoplasms and has higher frequency of theJAK2 V617F mutation. Hemorrhagic stroke is rare in PV, and myelofibrosis is secondary to PV. A 76-year-old Japanese man was diagnosed as PV with theJAK2 V617F mutation at the age of 63 years. He developed anemia together with secondary myelofibrosis, and then 40 mg ruxolitinib was started at 70 years. At 76 years, he presented with apathy and was diagnosed with intracerebral hemorrhage (ICH) in the right thalamus. Six months later, he developed multiple ICHs in bilateral cerebellar hemispheres. Leukocyte count was 57,600/ μL, ...
Source: Case Reports in Neurology - June 7, 2022 Category: Neurology Source Type: research
